Vaxart, Inc. · OTC:VXRT
Vaxart — Technical Presentation (May 2021)
16 slides from Vaxart's technical presentation, May 3, 2021
Slide 1: KOL Event: Unlocking the Full Potential of Oral Vaccines
may 2024 KOL Event UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES
Slide 2: Forward-Looking Statement
Forward-Looking Statement VAXART ‘This presentation contains forwardlooking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this presentation regarding Vaxans strategy, prospects, plans and objectives, results {rom p
Slide 3: Oral Vaccines Based on VAAST Platform
Oral Vaccines Based on VAAST Platform VAXART Selected Mucosal Adjuvant “Hard Wired” in Vector Delivery System Non-replicating adenovirus with molecular adjuvant ORAL VACCINES OFFERS IMPORTANT INNOVATIVE PLATFORM FOR ADVANTAGES: SYSTEMIC AND LOCAL IMMUNITY * Potentially disruptive impact * Designed f
Slide 4: VAAST Oral Vaccines — Validated Platform In Humans
VAAST Oral Vaccines — Validated Platform In Humans VAXART Approximately 500 Subjects Dosed to Date Clinical Trials SUBJECTS Tablet Vaccines DOSED SAFETY Favorable safety and tolerability profile EFFICACY Reduction in influenza illness comparable with the leading " Safety marketed quadrivalent intram
Slide 5: Vaxart — COVID Vaccine Issues
Vaxart — COVID Vaccine Issues VAXART * Covid-19 is a significant health problem. Vaccines can be highly effective against the original parental strain * Several limitations for roll-out of a needle solution during a pandemic Need a qualified health care provider to administer — The first vaccines ap
Slide 6: Vaxart Takes Away the Needles
in Important Step is the time for injecting large & Al opulations: Vaxart Takes Away the Needles VAXART Rapid Emergence of new SARS-CoV-2 strains Vaccine \ 2 Rapid Distribution Development & Administration Get Off The Wheel — ead, 3) Vaxart’s solution B ure ae ene ea to produce, ee ite, and admi - c
Slide 7: VXA-COV2-101 Phase 1 Study Design and Schema
VXA-COV2-101 Phase 1 Study Design and Schema VAXART * Single Dose, Oral Tablet Study at Low and Medium Doses + Small Sentinel Cohort that was boosted * Primary (Safety) and Secondary (Immunogenicity) Endpoints Met Mia “a, Dose (205 oe No.of subets VXA-CoV2-1 1x10 1.U. —— SMC Review of Safety Data th
Slide 8: Solicited Symptoms Post Vaccination — Phase 1
Solicited Symptoms Post Vaccination — Phase | VAXART Solicited Symptom Low Dose High Dose (n=20) (n=15) 4 (20) 10 (66.7) Gastrointestinal Symptoms Diarrhea 0 (00) 426.7) Nausea 0 (00) 5 (33.3) Vomiting 0 (00) ° Abdominal Pain 1(5.0) 2 (13.3) General Symptoms Malaise/Fatigue 2 (10) 2 (13.3) Myalgia (
Slide 9: Oral vaccine candidate shows preferential Th1 responses, strong CD8 response
Vaxart’s oral vaccine candidate shows preferential Th1 responses, inducing a strong CD8 cytotoxic response VAXKART Spike protein (S) Nucleoprotein (N) 20 20- A a a £ £ g 154 . 8 154 g a $ ° 6 Q 5 = 107 oa = 10- a @ o a a ¢ c £ 4 2 8 5 o z a 3 2 ry g é 2 Vv ot 3 Cytokine Cytokine Restimulation with S
Slide 10: Oral Vaccine candidate generates robust CD8 T cell responses
Vaxart’s Oral Vaccine candidate generates robust CD8 T cell responses VAXART Vaxart’s Oral Vaccine candidate generates high numbers of S specific IFN-y, TNFa and CD107a producing T cells post immunization. IFN-y 305 ° 10 moose 2 2 ° | ° EY g r 9 g o @ o fy 9 8 5 8 6 £ o 9. a E E 2 ° ° = ° 8 7 8 g *
Slide 11: CD8 T cell responses compare favorably to mRNA vaccines
Vaxart’s Oral Vaccine candidate generates robust CD8 T cell responses — Compares favorably to the mRNA vaccines VAXART Induction of T cells responses measured 7 days after the first dose. Increase over day 1 for IFN-y and TNFa are shown s S a a4 o | ao a S s = 5 & E34 8 S 8 8 ° E % a i € z Frozen PB
Slide 12: Do Vaccine Induced T cells Cross React Against other huCoV?
Do Vaccine Induced T cells Cross React Against other 33) huCoV? VAXART * Tarke, et al, (Biorxiv 2021) showed that mRNA vaccines create cross-reactive T cells against other SARS-CoV-2 variants of concern (see below) * What about other Coronaviruses? Spike AIM CD8*T cells (%) 1 01 001 1 01 001 1 04 O0
Slide 13: Future Proof: cross reactive T cells to other coronaviruses
Future P roof: Vaxart’s ora | 1 th. ne cross reactive T cells to ot! % IFNy+ CD8 lymphocytes ° ° ° o 0° ° ° Qe ° 229— HKU1 NL63 OC43 Human Coronavirus virus [nus [sent 65 alpha alpha 65 ta 68 68 SARS-CoV beta 82 Response is combined to both S & N peptides. Increase measured after subtracting backgro
Slide 14: Why T cells may be important for COVID
Why T cells may be important for COVID VAXART ° Cross-protective and long-lasting — N protein responses to SARS-CoV-1 last 17 years after infection and cross-react to SARS-CoV-2 (Hellerstein, et al, Vaccine, 2020) ° People with agammaglobulinemia don’t die of COVID and have a mild course of infectio
Slide 15: Increased cross-reactive nasal IgA response to other coronaviruses
Vaxart immunized subjects have increased cross-reactive nasal IgA response to other coronaviruses VAXART 04 . co ° ote . ={ ° B00 10 Increased IgA antibodies to SARS-Cov-2 also leads to increased antibody responses to the S protein of other coronaviruses including SARS-CoV-1, MERS, and endemic commo
Slide 16: Vaxart — Next Steps
Vaxart — Next Steps VAXART ° Dose ranging study to start around mid-year ° Phase Il efficacy study later this year ° Evaluating new strain matched candidates in research — Made S only versions of the “California” and “South African” strains — Can our original vaccine approach provide protection as e